A small, phase 1 trial testing a new HIV vaccine delivered positive results in 97 percent of recipients.The vaccine was created from an engineered version of a protein within the HIV virus. This particle, according to an article on Science Alert, was designed to get the body ready to produce the neutralizing antibodies thought to be critical for HIV immunity.Forty-eight participants received either the vaccine or a placebo, while 35 of the 36 dosed with the vaccine showed an activation of antibody precursor B cells that could pave the way to immunity.The results of the study were published in the academic journal Science alongside World AIDS Day.
